The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Abstract
The effects of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin that produces the symptoms of Parkinson's disease, can be fully prevented in experimental animals by inhibiting monoamine oxidase B. On the basis of this observation, a double-blind, placebo-controlled study in patients with early Parkinson's disease was initiated to determine whether deprenyl (a selective monoamine oxidase B inhibitor) would delay the need for L-dopa therapy by slowing the progression of the disease. Fifty-four patients were randomly assigned to deprenyl (10 mg/day) or placebo treatment groups and followed until L-dopa therapy was indicated or until the patient had been in the study for 3 years. Analysis of Kaplan-Meier survival curves for each group showed that deprenyl delayed the need for L-dopa therapy; the average time until L-dopa was needed was 312.1 days for patients in the placebo group and 548.9 days for patients in the deprenyl group. Disease progression, as monitored by five different assessment scales, was slowed (by 40 to 83% per year) in the deprenyl group compared to placebo. Therefore, early deprenyl therapy delays the requirement for antiparkinsonian medication, possibly by slowing progression of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Self-citationMiller, R. G. (1981) · Cited by 3,336
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
Chiba, K., Trevor, A., & Castagnoli, N. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91293-2 · Cited by 1,097
Heikkila, R. E., Manzino, L., Cabbat, F. S., & Duvoisin, R. C. (1984) · Nature · doi:10.1038/311467a0 · Cited by 1,010
William Langston, J., Forno, L. S., Rebert, C. S., & Irwin, I. (1984) · Brain Research · doi:10.1016/0006-8993(84)90777-7 · Cited by 922
Parkinson’s Disease and Movement Disorders
(2005) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/10587 · Cited by 798
Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
Markey, S. P., Johannessen, J. N., Chiueh, C. C., Burns, R. S., & Herkenham, M. A. (1984) · Nature · doi:10.1038/311464a0 · Cited by 786
Pargyline Prevents MPTP-Induced Parkinsonism in Primates
Langston, J. W., Irwin, I., Langston, E. B., & Forno, L. S. (1984) · Science · doi:10.1126/science.6332378 · Cited by 581
Self-citationCritical analysis of the disability in Parkinson's disease.
Webster, D. D. (1968) · PubMed · Cited by 488
Langston, J. W., Irwin, I., Langston, E. B., & Forno, L. S. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90293-3 · Cited by 435
Self-citationCohen, G., Pasik, P., Cohen, B., Leist, A., Mytilineou, C., & Yahr, M. D. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90700-3 · Cited by 323
Recent Developments in J Ic Testing
Landes, J., & Begley, J. (1977) · Developments in Fracture Mechanics Test Methods Standardization · doi:10.1520/stp28700s · Cited by 295
Riederer, P., & Youdim, M. B. H. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb01747.x · Cited by 245
Book Review: Third Symposium on Parkinson's Disease
Turner, J. W. A. (1970) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591577006300567 · Cited by 214
Deprenyl suppresses the oxidant stress associated with increased dopamine turnover
Cohen, G., & Spina, M. B. (1989) · Annals of Neurology · doi:10.1002/ana.410260518 · Cited by 211
The striatal dopamine dependency of life span in male rats. Longevity study with (−)deprenyl
Knoll, J. (1988) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(88)90128-5 · Cited by 208
Mann, J. J. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810010047007 · Cited by 178
Halpern, J., & Brown, B. W. (1986) · Statistics in Medicine · doi:10.1002/sim.4780050303 · Cited by 34
Clinical Trial for Parkinson's Disease?
Lewin, R. A. (1985) · Science · doi:10.1126/science.3931220 · Cited by 31
Cited by
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Core assessment program for intracerebral transplantations (CAPIT)
Langston, J. W., Widner, H., Goetz, C. G., Brooks, D., Fahn, S., Freeman, T., & Watts, R. (1992) · Movement Disorders · doi:10.1002/mds.870070103 · Cited by 1,008
Self-citationThe oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Metadata
- Authors
- Tetrud, J. W., & Langston, J. W.
- Venue
- Science
- Published
- 1989-08-04
- Volume
- 245
- Issue
- 4917
- Pages
- 519-522
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1987655773
- Cited by
- 638
- References
- 22
- FWCI
- 53.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.